2024年7月12日 (五) 17:01的最后版本

Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide

[编辑] 摘要

16 只组织学诊断为血管肉瘤的狗接受了手术和多柔比星/环磷酰胺治疗。患者的特征，即年龄、大小和品种，与以前的研究相似。仅使用手术的历史对照来评估化疗的疗效。结果显示，接受联合治疗的局部疾病（I 期）狗的存活率有提高的趋势。中位生存期为 250 天，平均为 403 天。与单独接受手术治疗的历史对照组相比，联合治疗也改善了患有 I、II 和 III 期疾病的狗的生存时间。总中位生存期为202天，平均为285天。毒性包括轻度至中度中性粒细胞减少症（9/16）和临床体征（如嗜睡、厌食、呕吐、腹泻和发烧（13/16）。三只狗患有严重的中性粒细胞减少症，需要住院治疗和支持性治疗。一只狗死于败血症和相关并发症。在早期疾病患者中，使用多柔比星和环磷酰胺进行化疗似乎可以提高生存率，且发病率可接受。

Sixteen dogs with a histologic diagnosis of hemangiosarcoma were treated with surgery and doxorubicin/cyclophosphamide. The patients' characteristics, ie, age, size, and breed, were similar to those of previous studies. Historic controls for surgery alone were used to evaluate efficacy of the chemotherapy. The results show a trend of improved survival in dogs with localized disease (Stage I) receiving combination therapy. The median survival was 250 days, with a mean of 403 days. The survival times for dogs with stage I, II, and III disease was also improved with combination therapy, when compared to historical controls treated with surgery alone. The overall median survival was 202 days with a mean of 285 days. Toxicities included mild to moderate neutropenia (9 of 16) and clinical signs, such as lethargy, anorexia, vomiting, diarrhea, and fever (13 of 16). Three dogs had severe neutropenia requiring hospitalization and supportive care. One dog died from sepsis and related complications. Chemotherapy with doxorubicin and cyclophosphamide appears to improve survival with acceptable morbidity in patients with early stage disease.